Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Diamondback Energy, Inc. stock logo
FANG
Diamondback Energy
$143.28
+3.8%
$142.79
$114.00
$200.47
$41.48B1.092.12 million shs2.03 million shs
The Goldman Sachs Group, Inc. stock logo
GS
The Goldman Sachs Group
$741.84
+3.6%
$705.56
$439.38
$749.05
$224.59B1.381.76 million shs1.95 million shs
Moderna, Inc. stock logo
MRNA
Moderna
$27.12
+3.4%
$29.18
$23.15
$84.28
$10.55B1.838.39 million shs9.16 million shs
These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Diamondback Energy, Inc. stock logo
FANG
Diamondback Energy
0.00%+2.18%-1.39%+5.46%-25.03%
The Goldman Sachs Group, Inc. stock logo
GS
The Goldman Sachs Group
0.00%+1.55%+3.15%+23.85%+49.44%
Moderna, Inc. stock logo
MRNA
Moderna
0.00%-3.21%-20.26%+3.27%-68.70%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Diamondback Energy, Inc. stock logo
FANG
Diamondback Energy
4.9149 of 5 stars
4.52.03.30.04.02.52.5
The Goldman Sachs Group, Inc. stock logo
GS
The Goldman Sachs Group
4.7384 of 5 stars
2.24.04.23.02.12.52.5
Moderna, Inc. stock logo
MRNA
Moderna
4.6454 of 5 stars
4.02.00.04.62.72.51.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Diamondback Energy, Inc. stock logo
FANG
Diamondback Energy
3.04
Buy$193.3334.93% Upside
The Goldman Sachs Group, Inc. stock logo
GS
The Goldman Sachs Group
2.33
Hold$660.00-11.03% Downside
Moderna, Inc. stock logo
MRNA
Moderna
2.04
Hold$42.8858.12% Upside

Current Analyst Ratings Breakdown

Latest FANG, GS, and MRNA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/22/2025
Moderna, Inc. stock logo
MRNA
Moderna
Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetUnderperform ➝ Underperform$18.00 ➝ $15.00
8/20/2025
Diamondback Energy, Inc. stock logo
FANG
Diamondback Energy
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$163.00 ➝ $171.00
8/20/2025
Diamondback Energy, Inc. stock logo
FANG
Diamondback Energy
Raymond James Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetStrong-Buy ➝ Strong-Buy$221.00 ➝ $212.00
8/20/2025
Diamondback Energy, Inc. stock logo
FANG
Diamondback Energy
Melius Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$213.00
8/20/2025
Diamondback Energy, Inc. stock logo
FANG
Diamondback Energy
Melius
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$213.00
8/18/2025
Diamondback Energy, Inc. stock logo
FANG
Diamondback Energy
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$184.00 ➝ $186.00
8/15/2025
The Goldman Sachs Group, Inc. stock logo
GS
The Goldman Sachs Group
Zacks Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Strong-Buy
8/14/2025
Diamondback Energy, Inc. stock logo
FANG
Diamondback Energy
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$228.00 ➝ $222.00
8/14/2025
Diamondback Energy, Inc. stock logo
FANG
Diamondback Energy
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$210.00 ➝ $211.00
8/4/2025
Moderna, Inc. stock logo
MRNA
Moderna
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$40.00 ➝ $31.00
8/1/2025
Moderna, Inc. stock logo
MRNA
Moderna
Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$32.00
(Data available from 8/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Diamondback Energy, Inc. stock logo
FANG
Diamondback Energy
$11.07B3.75$21.94 per share6.53$136.52 per share1.05
The Goldman Sachs Group, Inc. stock logo
GS
The Goldman Sachs Group
$126.85B1.77$53.68 per share13.82$350.27 per share2.12
Moderna, Inc. stock logo
MRNA
Moderna
$3.24B3.26N/AN/A$28.33 per share0.96
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Diamondback Energy, Inc. stock logo
FANG
Diamondback Energy
$3.34B$14.0710.189.16N/A27.25%9.48%5.63%11/3/2025 (Estimated)
The Goldman Sachs Group, Inc. stock logo
GS
The Goldman Sachs Group
$14.28B$45.3816.3514.251.5812.37%14.32%0.89%10/21/2025 (Estimated)
Moderna, Inc. stock logo
MRNA
Moderna
-$3.56B-$7.530.00N/AN/A-94.31%-25.96%-20.09%11/6/2025 (Estimated)

Latest FANG, GS, and MRNA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/4/2025Q2 2025
Diamondback Energy, Inc. stock logo
FANG
Diamondback Energy
$2.72$2.67-$0.05$2.38$3.35 billion$3.68 billion
8/1/2025Q2 2025
Moderna, Inc. stock logo
MRNA
Moderna
-$2.99-$2.13+$0.86-$2.13$116.26 million$142.00 million
7/16/2025Q2 2025
The Goldman Sachs Group, Inc. stock logo
GS
The Goldman Sachs Group
$9.82$10.91+$1.09$10.91$13.53 billion$14.58 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Diamondback Energy, Inc. stock logo
FANG
Diamondback Energy
$4.002.79%N/A28.43%7 Years
The Goldman Sachs Group, Inc. stock logo
GS
The Goldman Sachs Group
$12.001.62%N/A26.44%13 Years
Moderna, Inc. stock logo
MRNA
Moderna
N/AN/AN/AN/AN/A

Latest FANG, GS, and MRNA Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
7/17/2025
The Goldman Sachs Group, Inc. stock logo
GS
The Goldman Sachs Group
quarterly$4.002.3%8/29/20258/29/20259/29/2025
8/14/2025
Diamondback Energy, Inc. stock logo
FANG
Diamondback Energy
quarterly$1.002.71%8/14/20258/14/20258/21/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Diamondback Energy, Inc. stock logo
FANG
Diamondback Energy
0.35
0.55
0.52
The Goldman Sachs Group, Inc. stock logo
GS
The Goldman Sachs Group
2.57
0.67
0.67
Moderna, Inc. stock logo
MRNA
Moderna
N/A
3.93
3.77

Institutional Ownership

CompanyInstitutional Ownership
Diamondback Energy, Inc. stock logo
FANG
Diamondback Energy
90.01%
The Goldman Sachs Group, Inc. stock logo
GS
The Goldman Sachs Group
71.21%
Moderna, Inc. stock logo
MRNA
Moderna
75.33%

Insider Ownership

CompanyInsider Ownership
Diamondback Energy, Inc. stock logo
FANG
Diamondback Energy
0.48%
The Goldman Sachs Group, Inc. stock logo
GS
The Goldman Sachs Group
0.55%
Moderna, Inc. stock logo
MRNA
Moderna
11.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
Diamondback Energy, Inc. stock logo
FANG
Diamondback Energy
1,983289.49 million288.10 millionOptionable
The Goldman Sachs Group, Inc. stock logo
GS
The Goldman Sachs Group
46,500302.72 million301.06 millionOptionable
Moderna, Inc. stock logo
MRNA
Moderna
5,800389.08 million346.28 millionOptionable

Recent News About These Companies

Candriam S.C.A. Lowers Stake in Moderna, Inc. $MRNA
Moderna, Inc. (MRNA) Down 35% YTD. Here Is Why
Leerink Partners Lowers Moderna (NASDAQ:MRNA) Price Target to $15.00
Podcast: The Politics & Business of mRNA Vaccine Investment Cuts
Nuveen LLC Invests $19.51 Million in Moderna, Inc. $MRNA
Moderna to Present at Upcoming Conferences in September 2025

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Diamondback Energy stock logo

Diamondback Energy NASDAQ:FANG

$143.28 +5.28 (+3.83%)
Closing price 08/22/2025 04:00 PM Eastern
Extended Trading
$143.48 +0.20 (+0.14%)
As of 08/22/2025 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Diamondback Energy, Inc., an independent oil and natural gas company, acquires, develops, explores, and exploits unconventional, onshore oil and natural gas reserves in the Permian Basin in West Texas. It focuses on the development of the Spraberry and Wolfcamp formations of the Midland basin; and the Wolfcamp and Bone Spring formations of the Delaware basin, which are part of the Permian Basin in West Texas and New Mexico. The company also owns and operates midstream infrastructure assets, in the Midland and Delaware Basins of the Permian Basin. Diamondback Energy, Inc. was founded in 2007 and is headquartered in Midland, Texas.

The Goldman Sachs Group stock logo

The Goldman Sachs Group NYSE:GS

$741.84 +25.89 (+3.62%)
Closing price 08/22/2025 03:59 PM Eastern
Extended Trading
$741.75 -0.09 (-0.01%)
As of 08/22/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

The Goldman Sachs Group, Inc., a financial institution, provides a range of financial services for corporations, financial institutions, governments, and individuals worldwide. It operates through Global Banking & Markets, Asset & Wealth Management, and Platform Solutions segments. The Global Banking & Markets segment provides financial advisory services, including strategic advisory assignments related to mergers and acquisitions, divestitures, corporate defense activities, restructurings, and spin-offs; and relationship lending, and acquisition financing, as well as secured lending, through structured credit and asset-backed lending and involved in financing under securities to resale agreements. This segment also offers client execution activities for cash and derivative instruments; credit and interest rate products; and provision of mortgages, currencies, commodities, and equities related products, as well as underwriting services. The Asset & Wealth Management segment manages assets across various classes, including equity, fixed income, hedge funds, credit funds, private equity, real estate, currencies, and commodities; and provides customized investment advisory solutions, wealth advisory services, personalized financial planning, and private banking services, as well as invests in corporate equity, credit, real estate, and infrastructure assets. The Platform Solutions segment offers credit cards and point-of-sale financing for purchase of goods or services. This segment also provides cash management services, such as deposit-taking and payment solutions for corporate and institutional clients. The Goldman Sachs Group, Inc. was founded in 1869 and is headquartered in New York, New York.

Moderna stock logo

Moderna NASDAQ:MRNA

$27.12 +0.90 (+3.43%)
Closing price 08/22/2025 04:00 PM Eastern
Extended Trading
$27.13 +0.01 (+0.04%)
As of 08/22/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.